Page 19 - Pharma Companies

Inform people about vaccine in simple language, PM tells manufacturers

Serum Institute in Pune will undertake mass production of Covishield vaccine developed by Oxford-Astra Zeneca

Modi to interact with 3 teams involved in developing Covid-19 vaccine

The Prime Minister's Office said in a tweet on Sunday that the three teams are from Gennova Biopharma, Biological E and Dr. Reddy's.

AstraZeneca-Oxford vaccine safe, Indian trials progressing smoothly: SII

Serum Institute of India said the Covid-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly

Laurus Labs inks deal to buy majority stake in Richcore for Rs 247 crore

Following the successful closure of thetransaction, Richcore will be renamed as Laurus Bio Pvt Ltd, it added

Tech transfer of Russian Covid vaccine Sputnik V kicks off at Indian sites

In September, DRL and RDIF had tied up to conduct clinical trials and distribute the vaccine in India.

Pfizer ends vaccine trial with 95% success rate, to apply for approval soon

Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the world.

Moderna's Covid-19 vaccine may come to India through govt route

Players like Indian Immunologicals willing to partner US firm to manufacture here

Moderna's Covid vaccine 94.5% effective, edges over Pfizer on storage

Its vaccine's temperature requirements give it an edge over Pfizer's for distribution in India

Moderna Inc on track to report coronavirus vaccine data in November

Hopes of the world soon getting an effective vaccine were raised on Monday

EU to buy up to 300 million doses of Pfizer-BioNTech Covid-19 vaccine

The European Commission will sign a deal to secure up to 300 million doses of the experimental coronavirus vaccine developed by BioNTech and Pfizer

Gland Pharma IPO: Expensive at a price tag of 30x the FY20 earnings

While prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-term

AstraZeneca Pharma India Q2 net profit up 83% at Rs 26.33 crore

Drug firm AstraZeneca Pharma India on Thursday reported an 83.48 per cent rise in its net profit at Rs 26.33 crore for the quarter ended September 2020. The company had posted a net profit of Rs 14.41 crore for the corresponding period of the previous fiscal, it said in a filing to the BSE. Revenue from operations stood at Rs 209.47 crore for the quarter under consideration. It was Rs 208.48 crore for the same period a year ago, it added. Shares of AstraZeneca Pharma India closed at Rs4,295.80per scrip on the BSE, up 0.40 per cent from their previous close.

Street concerns ease as Sun Pharma's specialty segment delivers in Q2

Upsides in the stock will depend on sustaining specialty and India sales growth

Strides Pharma to set up 800-mn capacity vaccine suite in Bengaluru

In talks with global players seeking manufacturing opportunity for potential Covid-19 vaccine

Novavax delays US trial of Covid-19 vaccine candidate to November

The US-based drug developer said data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021

Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore

Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE

Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Strong prospects of Biologics business keep Street positive on Biocon

Even though Q2 performance missed estimates, analysts expect a stronger second half

Oxford Covid-19 vaccine doing everything expected', independent study finds

The experts say that the novel analysis provides even greater clarity and detail about how the vaccine successfully provokes a strong immune response.

Roche Holding sales disappoint as drugs decline eclipses Covid-19 tests

The Swiss drugmaker's revenue rose 1% to 14.7 billion francs ($16.1 billion), the company said